According to a TMR analyst, “The global market for peptide therapeutics was pegged at US$21.3 bn in 2015 and is expected to rise to a valuation of US$46.6 bn by 2024. The market is expected to expand at a 9.10% CAGR from 2016 to 2024.” The core reason behind the substantial growth of the global market for peptide therapeutics is the growing prevalence of cancer. As indicated by the WHO, almost 7 million individuals face death from cancer consistently and there will be more than 16 million new growth cases each year by 2020. Since chemotherapy is confronting significant difficulties because of its powerlessness to convey the right measure of medication directly, the utilization of peptides in tumor treatment has expanded, opening new roads for future development.

Browse Full Report Details@ https://www.transparencymarketresearch.com/peptide-therapeutics-market.html

Going ahead, the rising rate of metabolic issue is probably going to make lucrative prospects for the players operating in the global peptide therapeutics market in the years to come. In any case, the absence of administrative models may confine the market from developing throughout the forecast period.

With peptides evolving as a potential therapeutic agent for the treatment of cancer, the cancer segment emerged as the key contributor to this market in 2015. The rising mortality rate, caused by cancer, has led to an increased focus of players towards the development of new drugs and products to combat the situation, which is influencing the market substantially. The technological advancements and extensive research and development activities are likely to fuel the uptake of peptide therapeutics for the treatment of cancer over the next few years.

Geographically, the worldwide market for peptide therapeutics has been segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. North America led the global market with a share of 38.8% in 2015 and is expected to maintain its dominance over the next few years. The advancements in the healthcare infrastructure and the advent of peptide therapeutics as a highly potent drug used in oncology and hormonal therapies are likely to boost the growth of the North America peptide therapeutics market in the near future.

Apart from this, the presence of well-established players in the U.S. is also projected to support this regional market over the forthcoming years. Europe, which stood second in 2015, is also anticipated to witness healthy growth in the years to come.

Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=418

The global peptide therapeutics market is extremely consolidated in nature. At the forefront of this market are Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Sanofi, Pfizer Inc., Novartis AG, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Co., Bachem Holding AG, and Amgen Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/